Form 4: Macrogenics VP Controller Vests, Sells Shares

Macrogenics' VP, Controller & Treasurer, Beth Ann Smith, reported the vesting of restricted stock units and subsequent sale of shares for tax withholding purposes.

Summary

• Beth Ann Smith, VP, Controller & Treasurer of Macrogenics Inc. (MGNX), reported changes in her beneficial ownership of common stock.
• On February 7, 2026, 2,617 restricted stock units (RSUs) vested, converting into common stock. These RSUs were part of a grant of 7,850 units on February 7, 2025, vesting in three equal installments.
• Concurrently on February 7, 2026, 1,011 shares of common stock were disposed of at a price of $1.81 per share, likely for tax withholding related to the RSU vesting.
• Following these transactions on February 7, 2026, Beth Ann Smith's direct beneficial ownership of common stock was 11,138 shares.
• On February 8, 2026, an additional 1,583 restricted stock units (RSUs) vested, converting into common stock. These RSUs were part of a grant of 4,750 units on February 8, 2024, also vesting in three equal installments.
• On February 8, 2026, 612 shares of common stock were disposed of at a price of $1.81 per share, likely for tax withholding related to the RSU vesting.
• Following these transactions on February 8, 2026, Beth Ann Smith's direct beneficial ownership of common stock was 12,109 shares.
• All reported transactions were made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction related to equity compensation, which typically has a neutral impact on sentiment as it reflects standard compensation practices rather than a change in company outlook.

Positives

• The vesting of restricted stock units represents a scheduled compensation event for a key executive, indicating continued alignment of management interests with shareholder value through equity incentives.

Negatives

• The sale of shares, although for tax withholding purposes, results in a reduction of the insider's direct beneficial ownership of common stock.

Risks

• The value of the vested shares and the remaining unvested restricted stock units is subject to the market price fluctuations of Macrogenics Inc. common stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting and tax-related sales are common occurrences for publicly traded companies. These events are typically part of an executive's compensation package and are generally not indicative of significant strategic shifts or changes in company fundamentals, but rather standard equity compensation practices.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation-related transactions. The disclosure provides transparency into executive equity ownership changes.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• The remaining two installments of the 7,850 restricted stock units granted on February 7, 2025, are expected to vest on February 7, 2027, and February 7, 2028.
• The final installment of the 4,750 restricted stock units granted on February 8, 2024, is expected to vest on February 8, 2027.

Key Dates

Recommendation

The filing details routine insider transactions involving the vesting of restricted stock units and subsequent sales for tax purposes. These are standard compensation events and do not provide new fundamental information to warrant a change in investment recommendation based solely on this filing. A 'hold' recommendation reflects the lack of new material information that would alter the investment thesis.

Keywords

Macrogenics, MGNX, Insider Transaction, Form 4, Restricted Stock Units, Stock Vesting, Officer Compensation, Equity Compensation, Beth Ann Smith, Rule 10b5-1